Logo

Astellas Reports Results of Fezolinetant in P-III (SKYLIGHT 4) Trial for the Treatment of Vasomotor Symptoms Associated with Menopause

Share this

Astellas Reports Results of Fezolinetant in P-III (SKYLIGHT 4) Trial for the Treatment of Vasomotor Symptoms Associated with Menopause

Shots:

  • The P-III (SKYLIGHT 4) trial evaluates fezolinetant in ~1800 women with VMS associated with menopause at ~180 sites within the US, Canada & EU
  • The primary objective of the study was to evaluate the effect of fezolinetant on endometrial health & the long-term safety & tolerability of fezolinetant. The results from the (SKYLIGHT 4) trial will be submitted for publication
  • The company will support the regulatory submissions of the (SKYLIGHT 4) study along with the two P-III (SKYLIGHT 1) & (SKYLIGHT 2) in the US & EU. If fezolinetant is approved by regulatory authorities, it will be 1st non-hormonal treatment option to reduce the frequency and severity of VMS associated with menopause

Ref: PR Newswire | Image: Astellas

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions